Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

This looks modestly favorable on trial facts alone. The study is Phase 2, sponsored by a large experienced oncology company, and uses durvalumab plus platinum chemotherapy in resectable or borderline resectable stage IIB-IIIB NSCLC, a setting where immunotherapy plus chemotherapy has strong biological and clinical plausibility. The primary endpoint is resection rate, which is a relatively practical efficacy endpoint and generally easier to hit than long-term event-free or overall survival. That lowers the bar for a “positive” readout if the protocol defines success against a historical benchmark rather than requiring superiority versus a control arm. Offsetting that, the enrolled population includes borderline resectable and stage IIIB patients, which can materially reduce conversion to definitive surgery because of progression, toxicity, or multidisciplinary reassessment. The endpoint also depends on operational execution and surgeon decision-making, not just tumor biology. With primary completion already past and the trial still listed active not recruiting, there is some timing and disclosure risk, but from design alone the probability of a positive result is better than even.

MDT-BRIDGE is a Phase 2, single-arm, non-randomized study of ~140 EGFR/ALK wild-type stage IIB-IIIB NSCLC patients receiving neoadjuvant durvalumab plus platinum chemo, with the primary endpoint being resection rate. Several factors favor a positive readout: (1) durvalumab has strong Phase 3 backing from AEGEAN showing significant pCR and EFS improvement in resectable NSCLC; (2) single-arm Phase 2 trials have a lower bar than randomized trials—no comparator arm is needed, just a clinically meaningful resection rate; (3) meta-analyses of neoadjuvant chemoimmunotherapy in stage III NSCLC show resection rates of 69-85%. However, the inclusion of borderline-resectable patients will lower the overall resection rate versus purely resectable cohorts. The primary completion date has already passed (Jan 2026 per ClinicalTrials.gov) with no results disclosed yet, creating disclosure timing uncertainty. The BR.31 trial's failure of adjuvant durvalumab alone is a modest negative signal, though the neoadjuvant chemo-IO setting is distinct. On balance, the established mechanism and achievable endpoint favor positive results, but the challenging patient population and lack of pre-specified success threshold temper confidence.

This Phase 2 trial evaluates neoadjuvant durvalumab plus platinum chemo followed by either surgery/adjuvant durvalumab or chemoradiotherapy/consolidation durvalumab in resectable/borderline resectable stage IIB-IIIB NSCLC. The primary endpoint is resection rate - a meaningful but relatively soft endpoint compared to survival. Durvalumab (Imfinzi) is an established checkpoint inhibitor with prior positive data in lung cancer (PACIFIC trial in Stage III). Neoadjuvant immunotherapy+chemo has demonstrated positive results in NSCLC (CheckMate-816 showed pCR benefit with nivolumab+chemo). AstraZeneca has strong oncology capabilities. However, Phase 2 with surgical endpoint introduces execution risk, and the comparison between surgery vs CRT pathways adds complexity. The trial is already past primary completion (-80 days), suggesting data may be maturing. Overall balanced view favors modest positive outcome given strong biological rationale and prior checkpoint inhibitor success, but Phase 2 uncertainty keeps confidence moderate.

This is a complex, multi-arm Phase 2 trial by AstraZeneca assessing a neoadjuvant/adjuvant durvalumab strategy in resectable NSCLC. The primary endpoint is resection rate, a surgical feasibility metric, not a traditional survival or pathological complete response (pCR) endpoint. While a positive signal on resection rate is plausible given the known safety profile of the regimen, the endpoint is softer and more operational. The 'borderline resectable' population introduces heterogeneity and potential for conversion to resectability, which could aid success. However, Phase 2 trials have higher failure rates, and the binary 'positive results' prompt lacks specificity—it could refer to meeting a statistical threshold for resection rate improvement over a historical benchmark, which is not provided. Execution risk is moderate as the trial is past primary completion. Overall, a slight edge to YES due to sponsor capability and the achievable nature of the endpoint, but with low confidence.

Phase 2 single-arm trial (likely, no comparator specified for primary) tests neoadjuvant durvalumab + platinum chemo in resectable/borderline resectable stage IIB-IIIB NSCLC, followed by surgery/adjuvant durva or CRT/consolidation durva. Primary endpoint is resection rate (proportion undergoing surgery aimed at complete resection within 40 days of last neoadjuvant dose), a high-quality surrogate in neoadjuvant NSCLC trials correlating with EFS/pCR/OS benefits. Patient population (IIB-IIIB, borderline subset) has baseline chemo-only resection ~60-75%; prior data from AEGEAN (Phase 3 durva+chemo: 83% resection vs 79% chemo) and CheckMate816/77 (nivo+chemo ~83-85%) show IO+chemo boosts feasibility/safety. AstraZeneca's operational excellence (PACIFIC/AEGEAN success) minimizes execution risk; enrollment complete, primary completion 80 days ago ensures data maturity. No design flaws (clear endpoint, standard regimen); disclosure risk low given sponsor track record. Success threshold likely 70-80% resection—highly achievable per benchmarks, yielding ~72% YES probability.

The MDT-BRIDGE Phase 2 trial evaluates neoadjuvant durvalumab plus chemotherapy in resectable/borderline Stage IIB-IIIB NSCLC. The primary endpoint is resection rate, a surgical feasibility metric rather than a stringent survival or pathological response endpoint. Given AstraZeneca's extensive durvalumab experience (e.g., PACIFIC, neoadjuvant studies), the drug's safety profile is well-characterized, mitigating operational cancellation risk. The primary completion date (Jan 2026) has passed, with status 'Active Not Recruiting', indicating the surgical phase is likely concluded. Resection rates in this population historically range 70-90% with standard care; adding immunotherapy is unlikely to reduce surgical feasibility. The trial design allows CRT alternative for unresectable cases, further de-risking the 'positive' resolution regarding successful surgical execution. Consequently, probability of a positive result is high.

This Phase 2 neoadjuvant study in resectable stage IIB-IIIB NSCLC has already passed its primary completion date by 80 days, suggesting data collection is complete. The primary endpoint is resection rate, a mechanistic/surgical endpoint rather than survival benefit. Neoadjuvant chemo-immunotherapy in NSCLC has shown promise (CheckMate-816 established nivolumab+chemo), but durvalumab's track record in perioperative settings is mixed. The AEGEAN trial showed EFS benefit with perioperative durvalumab, but this trial's design differs—testing both surgery+adjuvant and CRT consolidation arms. Key risks: resection rate is achievable but may not translate to meaningful survival benefit; the dual-arm structure complicates interpretation; AstraZeneca has not yet disclosed results despite completion, potentially signaling data underwhelming or requiring longer follow-up. Borderline resectable patients historically have lower surgical success rates. Without event-free or overall survival data, regulatory and commercial value remains uncertain.

Interim data from the phase 2 MDT-BRIDGE trial (LBA65) presented at ESMO 2025 demonstrated highly positive findings for the primary endpoint of resection rate. Among 84 patients in the interim analysis, the definitive resection rate was 85.7% (72/84). Notably, 95% of initially resectable patients remained resectable, and 82% of borderline resectable patients became resectable after just two cycles of neoadjuvant durvalumab plus chemotherapy. Lead investigators characterized the results as 'impressive' and explicitly noted that surgical outcomes were consistent with the successful Phase 3 AEGEAN trial. Given this strong early investigator endorsement and the exceptionally high proportion of successful definitive surgeries achieved in a challenging borderline-resectable population, the trial's final readout is almost certain to be officially declared positive.

The trial is a Phase 2 study assessing the efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy for resectable and borderline resectable stage IIB-IIIB NSCLC. The primary endpoint is resection rate, which is a relevant and measurable outcome. Given the intervention's mechanism and the patient population, there is a reasonable expectation of positive results. However, the study is still active and not yet completed, which introduces uncertainty.